



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HANAA ALY



Screening of Oral Tamoxifen Ocular Toxicity in Breast Cancer Patients

Thesis

Submitted to Faculty of Medicine, Ain Shams University for
partial fulfillment of Master Degree in Ophthalmology

Presented by

Mai Mohamed Ahmed Ahmed

M.B., B.Ch

*Faculty of Medicine, Misr University for Science and Technology
(MUST)*

Under Supervision of

Prof. Dr. Abdelrahman Gaber Salman

Professor of Ophthalmology

Faculty of Medicine, Ain Shams University

Dr. Randa Hesham Ali Abdelgawad

Lecturer of Ophthalmology

Faculty of Medicine, Ain Shams University

Dr. Ahmed Said Ibrahim Abd El Motaal

Lecturer of Clinical Oncology

Faculty of Medicine, Ain Shams University

Dr. Ahmed Tharwat Abdelfattah

Lecturer of Ophthalmology

Misr University for Science and Technology (MUST)

Faculty of Medicine, Ain Shams University
Cairo - Egypt - 2021

Acknowledgments

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Abdelrahman Gaber Salman**, Professor of Ophthalmology, Faculty of Medicine, Ain Shams University, for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Prof. Dr. Azza Mohamed Ahmed Said**, Professor of Ophthalmology, Faculty of Medicine – Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Randa Hesham Ali Abdelgawad**, Lecturer of Ophthalmology, Faculty of Medicine – Ain Shams University, for her keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I would like to thank **Dr. Ahmed Said Ibrahim Abd El Motaal**, Lecturer of Clinical Oncology, Faculty of Medicine – Ain Shams University, for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I'd like to express my respectful thanks and profound gratitude to **Dr. Ahmed Tharwat Abdelfattah**, Lecturer of Ophthalmology, Misr University for Science and Technology (MUST), for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I'd like to express my respectful thanks and profound gratitude to **Dr. Samah Mahmoud Fawzy**, lecturer of Ophthalmology, Faculty of Medicine – Ain Shams University, for her keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

Finally, would like to express my appreciation and gratitude to all my family, especially my caring and loving parents for their support till this work was completed.

Mai Mohamed Ahmed Ahmed

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Contents

Title	Page No.
List of Abbreviations.....	i
List of Tables	iii
List of F igures.....	vi
Introduction	1
Aim of the Work.....	4
Review of Literature	
Breast cancer	5
Ocular Toxicity of Tamoxifen	16
Diagnosis of Tamoxifen Ocular Toxicity	24
Patients and Methods	40
Results	49
Discussion.....	88
Conclusion.....	93
Recommendations.....	95
Summary	96
References	99
Arabic Summary	---

List of Abbreviations

Abb.	Full term
ASCO	American Society of Clinical Oncology
BCVA	Best Corrected Visual Acuity
BMI	Body mass index
BRCA	Breast Cancer gene
CMT	Central macular thickness
DNA	Deoxyribonucleic acid
EBCTCG	Early Breast Cancer Trialists' Collaborative Group
EPIC	European prospective investigation into cancer and nutrition
ER	Estrogen receptor
ERG	Electroretinography
ETDRS	Early Treatment Diabetic Retinopathy Study
GCC	Ganglion cell complex
HER-2	Human epidermal growth factor receptor 2
HRT	Hormone replacement therapy
IOP	Intraocular pressure
ISCEV	International Society for Clinical Electrophysiology of Vision
MAPK-ERK	Mitogen-activated protein kinases extracellular signal-regulated kinases
MD	Mean deviation
MFERG	multifocal electroretinogram
MPOD	Macular pigment optical density
NCI	Egypt National Cancer Institute
PI3K/Akt	Phosphoinositide-3-Kinase, protein Kinase B
PERG	Pattern electroretinogram
PR	Progesterone receptor
PROS	Preserved photoreceptor outer segment

RNFL	Retinal nerve fiber layer
RPE	Retinal pigment epithelium
SD	Standard deviation
SD-OCT	Spectral domain optical coherence tomography
SERM	Selective estrogen receptor modulator
SWS	Short wavelength sensitive
TNM	Tumor-Node-Metastasis staging
VEP	Visual evoked potential

L ist of T ables

Table No.	Title	Page No.
1	Mean age of studied patients.....	49
2	Mean duration of tamoxifen therapy.	50
3	Duration of tamoxifen therapy divided into 2 groups.	50
4	BCVA (logMAR) and its correlation to duration of tamoxifen therapy.....	51
5	Summary of BCVA (logMAR) difference between two groups regarding duration of tamoxifen intake	52
6	Mean value of IOP value and its correlation to duration of tamoxifen therapy.....	52
7	Mean IOP value difference between two groups regarding duration of tamoxifen intake	53
8	Summary of cup disc values and its correlation to tamoxifen intake duration	54
9	Summary of cup disc values and disc parameters difference between two groups regarding duration of tamoxifen intake	54
10	RPE mottling distribution among the studied patients.....	55
11	RPE mottling affection difference between two groups regarding duration of tamoxifen	55
12	Descriptive values of mean average peripapillary Retinal Nerve Fiber layer (RNFL) thickness in our study.....	57
13	Summary of average peripapillary Retinal Nerve Fiber Layer (RNFL) values and their correlation to tamoxifen therapy duration	58
14	Descriptive data of average peripapillary Retinal Nerve fiber layer (RNFL) affection.....	59
15	Summary of difference peripapillary Retinal Nerve Fiber layer (RNFL) values between both groups regarding duration of tamoxifen intake in both groups	60

L ist of T ables (cont..)

Table No.	Title	Page No.
16	Summary of difference peripapillary Retinal Nerve fiber layer (RNFL) affection between both groups regarding duration of tamoxifen intake	61
17	Descriptive values of mean macular thickness in our study in different quadrants.....	64
18	Descriptive data of total macular thickness affection in our study.....	65
19	Summary of mean macular thickness in different quadrants and its correlation to tamoxifen intake duration	66
20	Summary of mean macular thickness comparing both groups.....	67
21	Summary of total macular thickness affection between both groups regarding duration of tamoxifen intake	68
22	Summary of average Ganglion cell complex (GCC) thickness values	71
23	Descriptive data of Average Ganglion cell complex (GCC) affection.....	72
24	Summary of average Ganglion cell complex (GCC) and its correlation to duration of tamoxifen.....	73
25	Summary of mean of average Ganglion Cell Complex (GCC) complex thickness values difference in both groups regarding duration of tamoxifen intake	74
26	Summary of average Ganglion Cell Complex (GCC) complex affection difference between both groups.....	75
27	IS/OS layer thickness disruption among the studied patients	76
28	ERG affection among the studied patients.....	78
29	Color vision affection among the studied patients	81

L ist of T ables (cont..)

Table No.	Title	Page No.
30	Summary of color vision affection to duration of tamoxifen therapy	81
31	Summary of total macular thickness values to color vision affection	83
32	Summary of parameters in our study and their correlation to duration of tamoxifen	86
33	Descriptive data of parameters used in our study and their correlation to duration of tamoxifen therapy	87

L ist of Figures

Fig. No.	Title	Page No.
1	Distribution of estimated female breast cancer new cases, deaths, and 5-year prevalence by world region, 2012	6
2	Breast cancer incidence rates/100,000 person-years by age group and year of diagnosis, 1999–2008.....	7
3	Mechanisms of Action and Resistance in Estrogen Receptor (ER)–Targeted Therapy	10
4	Fundus photography of both eyes of one patient showing crystalline deposits in perifoveal area	19
5	A and B, Slit-lamp external photograph of the right eye shows subepithelial crystallin-like substance deposition in the cornea	22
6	Slit-lamp examination (A) and cobalt blue filter after fluorescein instillation (B) of the patient’s right eye depicting whorl-like, subepithelial deposits sparing the periphery and central cornea.....	22
7	Ishihara color vision test plates	25
8	Ishihara color vision test plates	26
9	SD-OCT of the right eye. The black arrow showed the hyperreflective substances between the ganglion cell layer and inner plexiform layer correspond with the refractile deposits.....	29
10	SD-OCT of the left eye. A defect in the outer retinal layer with sharp edges can be seen.....	29
11	SD-OCT of the right eye. A disruption of the photoreceptor layer can be seen.	30
12	SD-OCT showed bilateral disruption of the ellipsoid zone and interdigitation zone	30
13	The biphasic waveform of the ERG of a normal patient	31

L ist of Figures (cont..)

Fig. No.	Title	Page No.
14	Representative fullfield ERG waveforms from a tamoxifen subject according to The International Society for Clinical Electrophysiology of Vision (ISCEV) standard protocol	33
15	A typical standard PERG.....	35
16	(A) MFERG trace array derived from 103 mfERG responses of the first-order kernel. (B) Three-dimensional plot of multifocal ERG response density.....	37
17	Visual evoked potential in a case of tamoxifen toxicity.	39
18	Fransworth panel D-15 device used in our study.	43
19	Fransworth panel D-15 device used in our study.	43
20	Retnia scan RS 3000 advance nidek OCT device used in our study.....	44
21	RETI port/scan 21 Electrophysiology device used in our study.....	45
22	OCT optic nerve scan of one of our patients.	46
23	OCT-macula map of one of our patients.	46
24	OCT-of ganglion cell complex (GCC) of one of our patients.....	47
25	Pie diagram showing groups of tamoxifen therapy intake.....	51
26	OCT optic nerve scan of one of our patients shows within normal average RNFL thickness in both eyes.....	62
27	OCT optic nerve scan of one of our patients shows thinning of average RNFL thickness in superior half of right eye.	62
28	OCT optic nerve scan of one of our patients shows below normal thinning of average RNFL thickness in nasal quadrant of rt eye and borderline thinning of average RNFL thickness in nasal quadrant of left eye.	63

L ist of Figures (cont..)

Fig. No.	Title	Page No.
29	OCT- macula map of one of our patients shows within normal average total macular thickness, GCC shows within average normal thickness in both eyes.	69
30	OCT macula map of one of our patients shows borderline thinning of the average total macular thickness in nasal and lower quadrants in outer ring in left eye.....	69
31	OCT-macula map of one of our patients shows borderline thinning of the central macular thickness of both eyes and borderline thinning in superior quadrant of left eye and temporal quadrant of right eye in the 3 mm zone	70
32	Pie diagram showing IS/OS layer thickness among the studied group (N=50).....	76
33	OCT-macula radial of one of our patients shows interruption in IS/OS layer thickness in both eyes.	77
34	OCT-macula radial of one of our patients shows interruption in IS/OS layer thickness in both eyes.	77
35	PERG of one of our patients shows delayed N95 wave in Right eye.	79
36	MFERG of one of our patients showed reduced P1 amplitude in ring 1.....	80
37	Pie diagram showing color vision defects distribution among the studied group (N=50).....	82
38	Fransworth D-15 Hue test of patient in our study with normal color vision.	84
39	Fransworth D-15 Hue test of patient in our study with tritanomaly.	84
40	Fransworth D-15 Hue test of patient in our study with protanomaly.	85
41	Fransworth D-15 Hue test of patient in our study with deutanomaly.	85